U.S. markets open in 1 hour 44 minutes
  • S&P Futures

    4,285.00
    -32.75 (-0.76%)
     
  • Dow Futures

    33,735.00
    -308.00 (-0.90%)
     
  • Nasdaq Futures

    13,925.75
    -61.00 (-0.44%)
     
  • Russell 2000 Futures

    1,899.90
    -28.40 (-1.47%)
     
  • Crude Oil

    87.35
    +0.74 (+0.85%)
     
  • Gold

    1,788.90
    -4.20 (-0.23%)
     
  • Silver

    22.60
    -0.07 (-0.31%)
     
  • EUR/USD

    1.1142
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    1.8070
    0.0000 (0.00%)
     
  • Vix

    32.03
    +0.07 (+0.22%)
     
  • GBP/USD

    1.3381
    -0.0000 (-0.00%)
     
  • USD/JPY

    115.5740
    +0.2720 (+0.24%)
     
  • BTC-USD

    36,277.30
    -315.28 (-0.86%)
     
  • CMC Crypto 200

    821.92
    +2.41 (+0.29%)
     
  • FTSE 100

    7,441.96
    -112.35 (-1.49%)
     
  • Nikkei 225

    26,717.34
    +547.04 (+2.09%)
     

Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • SGHT

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference.

A recording of the fireside chat will be available beginning on Monday, November 22, 2021, at 10:00am ET. Interested parties may access the webcast on the “Investors” section of the company’s website at: https://investors.sightsciences.com/

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform standards of care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids. The Company has a 510(k) pending for the clearance of the TearCare System for an expanded indication for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2021 Sight Sciences. All rights reserved.

Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com